[Sponsored Report] Binggrae’s Doctor Capsule 100 is still a success

Home > National > Guest Reports

print dictionary print

[Sponsored Report] Binggrae’s Doctor Capsule 100 is still a success

테스트

Doctor Capsule 1000 has seen a huge boost in sales since its renewal in August. [BINGGRAE]

Since the renewal of Doctor Capsule 1000 in August, Binggrae has seen a huge boost in sales.

The double capsule lactobacillus covers up the probiotics and lowers the chances of lactobacillus dying out before it gets to the intestines.

A recent study proves that the Doctor Capsule 1000 lactobacillus was 1,000 times more likely to survive compared to powder lactobacillus.

Binggrae has selected blue-eyed Korean doctor Ihn Yo-han as their main spokesmodel for the product.

Ihn is a doctor working at Yonsei University’s Severance Hospital in western Seoul.

His versatility, seen through his numerous appearances in the media, as well as in the medical and educational fields, seemed like a perfect fit with the trustworthy image of Doctor Capsule 1000.

Binggrae’s Doctor Capsule was first introduced in 1997, and it was the first product to get a patent in the fermented milk manufacturing field. It has been a steady seller for Binggrae ever since.

“After the renewal of Doctor Capsule, sales are steadily on the rise. We are planning to demonstrate our value through real data that consumers can actually trust and become the best-seller in the market,” said an official from Binggrae.

By Kim Seung-Jun [kim.Seungjun@joongang.co.kr]

More in Guest Reports

Ambassador marks Singapore’s 55th National DayHoliday falls one day after 45th anniversary of relations with Korea

Hyundai E&C’s Daegu complex boasts convenience

[SPONSORED REPORT] Hyundai Mobis strengthens its global R&D network

[SPONSORED REPORT] Posco practices its own motto by giving back

[SPONSORED REPORT] Chong Kun Dang offers solution for parasitic worms

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now